ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ABMD
  • CUSIP: 00365410
  • Web: www.abiomed.com
  • Market Cap: $6.29984 billion
  • Outstanding Shares: 43,578,000
Average Prices:
  • 50 Day Moving Avg: $143.37
  • 200 Day Moving Avg: $128.14
  • 52 Week Range: $95.14 - $147.54
  • Trailing P/E Ratio: 125.00
  • Foreward P/E Ratio: 58.04
  • P/E Growth: 2.63
Sales & Book Value:
  • Annual Revenue: $445.3 million
  • Price / Sales: 14.31
  • Book Value: $10.37 per share
  • Price / Book: 14.10
  • EBIDTA: $97.93 million
  • Net Margins: 16.13%
  • Return on Equity: 13.03%
  • Return on Assets: 10.98%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 5.95%
  • Quick Ratio: 4.20%
  • Average Volume: 319,722 shs.
  • Beta: 0.2
  • Short Ratio: 4.97
Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, July, 27th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.42 by $0.03. The company had revenue of $132.47 million for the quarter, compared to analysts' expectations of $130.83 million. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. ABIOMED's quarterly revenue was up 28.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.29 earnings per share. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

7 brokers have issued twelve-month price targets for ABIOMED's stock. Their forecasts range from $140.00 to $170.00. On average, they expect ABIOMED's share price to reach $152.50 in the next twelve months. View Analyst Ratings for ABIOMED.

What are analysts saying about ABIOMED stock?

Here are some recent quotes from research analysts about ABIOMED stock:

  • 1. According to Zacks Investment Research, "Over the last one month, Abiomed has been trading above the broader Medical Instruments industry. Management expects that robust demand for the Impella product line will continue to drive Abiomed’s top line. The company’s expanding product portfolio will improve penetration into both the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that both Impella 2.5 and CP continue to add centers in the U.S. The company also announced the successful launch of the Abiomed Impella Quality Program in fiscal 2017 to improve clinical outcomes. Also, cost-savings efforts remain encouraging. Furthermore, a rising estimate revision trend for the current year indicates a pocket of opportunity for the stock. However, intensifying competition in the niche markets is likely to mar prospects over the long haul." (7/13/2017)
  • 2. Jefferies Group LLC analysts commented, "We hosted ABMD management for a series of meetings. As can be expected for a company that is growing revenue 40%+ and for a stock that has increased 33% this year (after 137% last year), the discussions focused on the sustainability of the company’s growth prospects. The outlook remains very encouraging and we offer some observations below. ABMD remains a top pick. ABMD remains at top pick. There are few growth stories that rival ABMD for large, under penetrated markets; established reimbursement; and no appreciable competition. Since the first PMA approval five quarters ago, the company has seen US Impella revenue growth average 49%. The company still only sells about 15k pumps a year in the US despite a market opportunity that is over 200k, a penetration rate of just 7%." (8/9/2016)

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

  • Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
  • Michael J. Tomsicek, Chief Financial Officer, Vice President, Treasurer
  • David M. Weber, Chief Operating Officer
  • William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations
  • Andrew J. Greenfield, Vice President, General Manager - Global Marketing
  • Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
  • Dorothy E. Puhy, Lead Independent Director
  • Jeannine M. Rivet, Independent Director
  • Eric A. Rose M.D., Independent Director
  • Martin P. Sutter, Independent Director

Who owns ABIOMED stock?

ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rockefeller Financial Services Inc. (0.51%), State Treasurer State of Michigan (0.33%), Congress Asset Management Co. MA (0.15%), Russell Investments Group Ltd. (0.11%), Strs Ohio (0.08%) and Texas Permanent School Fund (0.07%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Bank of Montreal Can, Rockefeller Financial Services Inc., Municipal Employees Retirement System of Michigan, First Quadrant L P CA, Congress Asset Management Co. MA and Oakbrook Investments LLC. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley and Michael R Minogue. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was bought by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Insight Capital Research & Management Inc., Handelsbanken Fonder AB, Eqis Capital Management Inc., Fox Run Management L.L.C., CENTRAL TRUST Co, Lebenthal Lisanti Capital Growth LLC and Creative Planning. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $146.25.

MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $152.50 (4.27% upside)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Piper Jaffray CompaniesReiterated RatingOverweight$145.00 -> $160.00MediumView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 -> $140.00LowView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
3/30/2017Leerink SwannBoost Price TargetOutperform$140.00 -> $150.00LowView Rating Details
1/8/2017BTIG ResearchReiterated RatingBuy$170.00N/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/AView Rating Details
8/9/2016Jefferies Group LLCBoost Price TargetBuy$130.00 -> $145.00N/AView Rating Details
4/10/2016Benchmark Co.Reiterated RatingBuy$145.00N/AView Rating Details
10/30/2015Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$85.00N/AView Rating Details
10/29/2015Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
8/17/2015CRT CapitalInitiated CoverageBuyN/AView Rating Details
8/14/2015StephensReiterated RatingOverweight$103.00 -> $128.00N/AView Rating Details
8/5/2015Northland SecuritiesBoost Price TargetMarket Perform$60.00 -> $80.00N/AView Rating Details
(Data available from 7/29/2015 forward)


Earnings History for ABIOMED (NASDAQ:ABMD)
Earnings by Quarter for ABIOMED (NASDAQ:ABMD)
Earnings History by Quarter for ABIOMED (NASDAQ ABMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.36N/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ABIOMED (NASDAQ:ABMD)
2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.78
2019 EPS Consensus Estimate: $2.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176$0.20$0.29$0.24
Q2 20173$0.22$0.24$0.23
Q3 20173$0.29$0.31$0.30
Q4 20172$0.32$0.32$0.32
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.50$0.48
Q4 20183$0.50$0.61$0.55
Q1 20192$0.58$0.61$0.60
Q2 20191$0.51$0.51$0.51
Q3 20191$0.63$0.63$0.63
Q4 20192$0.65$0.82$0.74
(Data provided by Zacks Investment Research)


Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ:ABMD)
Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 90.77%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.24View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.00View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.00View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.00View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.00View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.00View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.40View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.00View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.60View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.00View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.00View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.00View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.00View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.00View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.00View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.00View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.00View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.00View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.00View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.04View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.00View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.90View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.00View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.40View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.00View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.98View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.40View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.00View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.00View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.90View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.00View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.00View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.40View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.20View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ABIOMED (NASDAQ:ABMD)
Latest Headlines for ABIOMED (NASDAQ:ABMD)
nasdaq.com logoAbiomed (ABMD) Q1 Earnings and Revenues Beat Estimates - Nasdaq
www.nasdaq.com - July 28 at 3:39 PM
finance.yahoo.com logoAbiomed (ABMD) Q1 Earnings and Revenues Beat Estimates
finance.yahoo.com - July 28 at 3:39 PM
fool.com logoAbiomed, Inc. Starts Its Fiscal Year on a High Note
www.fool.com - July 28 at 9:20 AM
finance.yahoo.com logoInvestor Network: ABIOMED, Inc. to Host Earnings Call
finance.yahoo.com - July 27 at 8:33 PM
finance.yahoo.com logoAbiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
finance.yahoo.com - July 27 at 8:33 PM
finance.yahoo.com logoEdited Transcript of ABMD earnings conference call or presentation 27-Jul-17 12:00pm GMT
finance.yahoo.com - July 27 at 8:33 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Issues Earnings Results
www.americanbankingnews.com - July 27 at 4:59 PM
americanbankingnews.com logoPiper Jaffray Companies Reiterates "Overweight" Rating for ABIOMED, Inc. (NASDAQ:ABMD)
www.americanbankingnews.com - July 27 at 4:50 PM
finance.yahoo.com logoAbiomed beats Street 1Q forecasts
finance.yahoo.com - July 27 at 3:24 PM
nasdaq.com logoCheck Out 5 Profitable Stocks for Spectacular Gains - Nasdaq.com - Nasdaq
www.nasdaq.com - July 26 at 3:17 PM
nasdaq.com logoABIOMED Reaches Analyst Target Price - Nasdaq.com - Nasdaq
www.nasdaq.com - July 26 at 3:17 PM
finance.yahoo.com logoWhere Abiomed Plans to Expand Impella CP’s Label
finance.yahoo.com - July 25 at 3:20 PM
finance.yahoo.com logoUnderstanding Abiomed’s Changing Payment Structure Plans for Impella
finance.yahoo.com - July 25 at 3:20 PM
finance.yahoo.com logoWhy Abiomed Expects to Benefit from Impella in Cardiogenic Shock
finance.yahoo.com - July 24 at 2:00 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 24 at 10:16 AM
finance.yahoo.com logoAbiomed Aims to Expand Impella RP’s Penetration Going Forward
finance.yahoo.com - July 21 at 9:40 PM
finance.yahoo.com logoAbiomed Impella Quality Program Will Boost Demand in Fiscal 2018
finance.yahoo.com - July 21 at 4:37 PM
finance.yahoo.com logoAbiomed in 2017: The Analysts’ View
finance.yahoo.com - July 20 at 8:19 PM
americanbankingnews.com logoABIOMED, Inc. (NASDAQ:ABMD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:02 AM
americanbankingnews.com logo$129.70 Million in Sales Expected for ABIOMED, Inc. (NASDAQ:ABMD) This Quarter
www.americanbankingnews.com - July 16 at 8:00 AM
americanbankingnews.com logo$0.42 Earnings Per Share Expected for ABIOMED, Inc. (NASDAQ:ABMD) This Quarter
www.americanbankingnews.com - July 14 at 6:20 PM
finance.yahoo.com logoAbbott Partners Bigfoot Biomedical to Expand in Diabetics
finance.yahoo.com - July 14 at 5:10 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 13 at 4:52 PM
nasdaq.com logoAbiomed (ABMD) Scores a Strong Buy Right Now: Here's How
www.nasdaq.com - July 13 at 3:44 PM
finance.yahoo.com logoAbiomed (ABMD) Scores a Strong Buy Right Now: Here's How
finance.yahoo.com - July 13 at 3:44 PM
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 3:44 PM
americanbankingnews.com logoABIOMED, Inc. (NASDAQ:ABMD) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - July 10 at 11:32 PM
globenewswire.com logoAbiomed First Quarter Fiscal 2018 Earnings and Conference Call Notification - GlobeNewswire (press release)
globenewswire.com - July 6 at 4:46 PM
feeds.benzinga.com logoAbiomed First Quarter Fiscal 2018 Earnings and Conference Call Notification
feeds.benzinga.com - July 6 at 7:38 AM
americanbankingnews.com logoZacks Investment Research Downgrades ABIOMED, Inc. (NASDAQ:ABMD) to Hold
www.americanbankingnews.com - July 5 at 2:06 PM
globenewswire.com logoNew Study with Abiomed's Impella 2.5® Heart Pump Demonstrates ... - GlobeNewswire (press release)
globenewswire.com - July 1 at 1:40 AM
nasdaq.com logoNew Study with Abiomed's Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart ... - Nasdaq
www.nasdaq.com - June 30 at 3:24 PM
finance.yahoo.com logoNew Study with Abiomed's Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery
finance.yahoo.com - June 30 at 3:24 PM
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : June 30, 2017
finance.yahoo.com - June 30 at 3:24 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Downgraded by BidaskClub
www.americanbankingnews.com - June 28 at 8:39 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 27 at 8:42 AM
americanbankingnews.com logo Analysts Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $129.70 Million
www.americanbankingnews.com - June 22 at 10:18 AM
americanbankingnews.com logo Brokerages Anticipate ABIOMED, Inc. (ABMD) to Post $0.42 Earnings Per Share
www.americanbankingnews.com - June 20 at 4:08 PM
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 3:18 PM
finance.yahoo.com logoABIOMED, Inc. :ABMD-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 3:19 PM
americanbankingnews.com logoABIOMED, Inc. to Post Q1 2018 Earnings of $0.41 Per Share, William Blair Forecasts (ABMD)
www.americanbankingnews.com - June 12 at 8:12 AM
americanbankingnews.com logoABIOMED (ABMD) & GenMark Diagnostics (GNMK) Critical Comparison
www.americanbankingnews.com - June 10 at 10:52 PM
nasdaq.com logoWhy Is Abiomed (ABMD) Up 7.8% Since the Last Earnings Report ... - Nasdaq
www.nasdaq.com - June 9 at 3:18 PM
finance.yahoo.com logoHeart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology
finance.yahoo.com - June 9 at 3:18 PM
americanbankingnews.com logoABIOMED, Inc. to Post Q1 2019 Earnings of $0.58 Per Share, William Blair Forecasts (ABMD)
www.americanbankingnews.com - June 9 at 2:26 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Earns Outperform Rating from Analysts at William Blair
www.americanbankingnews.com - June 8 at 10:58 AM
finance.yahoo.com logoAbiomed (ABMD) at 52-Week High: What's Driving the Stock?
finance.yahoo.com - June 6 at 10:50 AM
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : May 31, 2017
finance.yahoo.com - May 31 at 3:17 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 31 at 8:34 AM
finance.yahoo.com logoAbiomed to Present at the Jefferies Healthcare Conference
finance.yahoo.com - May 30 at 3:19 PM



ABIOMED (ABMD) Chart for Saturday, July, 29, 2017

This page was last updated on 7/29/2017 by MarketBeat.com Staff